Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
Jii Bum Lee, Hye Ryun Kim, Sang‐Jun Ha
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 115

Showing 1-25 of 115 citing articles:

The Treatment of Advanced Melanoma: Therapeutic Update
Alessia Villani, Luca Potestio, Gabriella Fabbrocini, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6388-6388
Open Access | Times Cited: 82
Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment
Junyu Qiu, Zilin Cheng, Zheng Jiang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5490-5490
Open Access | Times Cited: 17
Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells
Myeong Joon Kim, Kyung Soo Kim, Hyo Jin Park, et al.
Nature Immunology (2022) Vol. 24, Iss. 1, pp. 148-161
Closed Access | Times Cited: 48
Molecular Mechanisms of T Helper Cell Differentiation and Functional Specialization
Gap Ryol Lee
Immune Network (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 25
Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells
Narendiran Rajasekaran, Xiaoguang Wang, Sruthi Ravindranathan, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 3
Open Access | Times Cited: 9
Next-generation combination approaches for immune checkpoint therapy
Sangeeta Goswami, Kristen E. Pauken, Linghua Wang, et al.
Nature Immunology (2024) Vol. 25, Iss. 12, pp. 2186-2199
Closed Access | Times Cited: 9
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management
Conrad Russell Y. Cruz, Maria José Albuquerque Santos, Sharada Wali, et al.
Immunotherapy (2025), pp. 1-11
Closed Access | Times Cited: 1
T-cell repertoire diversity: friend or foe for protective antitumor response?
Nicla Porciello, Ornella Franzese, Lorenzo D’Ambrosio, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 38
The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions
Despoina Eugenia Kiousi, Antonia Z. Kouroutzidou, Konstantinos Neanidis, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2101-2101
Open Access | Times Cited: 21
Management of Advanced Invasive Melanoma: New Strategies
Alessia Villani, Massimiliano Scalvenzi, Giuseppe Micali, et al.
Advances in Therapy (2023) Vol. 40, Iss. 8, pp. 3381-3394
Open Access | Times Cited: 18
The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy
Damián Kovalovsky, Satish Noonepalle, Manasa Suresh, et al.
Science Advances (2024) Vol. 10, Iss. 46
Open Access | Times Cited: 6
Nanomedicines for Overcoming Cancer Drug Resistance
Tingting Hu, Hanlin Gong, Jiayue Xu, et al.
Pharmaceutics (2022) Vol. 14, Iss. 8, pp. 1606-1606
Open Access | Times Cited: 27
Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light
Jie Zhang, Kang-Hui Wu, Cuicui Shi, et al.
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 12, pp. 1777-1792
Open Access | Times Cited: 26
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
Jaromir Hunia, Karol Gawalski, Aleksandra Szredzka, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 23
Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies
Rachel SJ Wong, Rebecca JM Ong, Joline SJ Lim
Cancer Drug Resistance (2023) Vol. 6, Iss. 4, pp. 768-87
Open Access | Times Cited: 16
Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers
Dong Yeul Lee, Talha Salahuddin, Jabed Iqbal
Current Oncology (2023) Vol. 30, Iss. 2, pp. 2127-2143
Open Access | Times Cited: 13
Nanotechnology Applications in Breast Cancer Immunotherapy
Ruijie Wang, Pramod Kumar, Moataz Reda, et al.
Small (2023)
Closed Access | Times Cited: 13
Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy
Hsing-Wu Chen, Yao-Wen Kuo, Chung‐Yu Chen, et al.
The Oncologist (2024) Vol. 29, Iss. 4, pp. e498-e506
Open Access | Times Cited: 5
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?
Akshara Vaddi, Holly J. Hulsebus, Emily L. O’Neill, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 2, pp. 1601-1624
Open Access | Times Cited: 5
Neutrophils: Musketeers against immunotherapy
Kashif Rafiq Zahid, Umar Raza, Soumya Tumbath, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 22
Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021)
Shanshan Yang, Suya Zhao, Yixiang Ye, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Roles of Virtual Memory T Cells in Diseases
Joon Seok, Sung‐Dong Cho, Seong Jun Seo, et al.
Immune Network (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Biomimetic Cell-Derived Nanoparticles: Emerging Platforms for Cancer Immunotherapy
Tingting Hu, Yuezhou Huang, Jing Liu, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1821-1821
Open Access | Times Cited: 11
Recent Advances in Artificial Intelligence to Improve Immunotherapy and the Use of Digital Twins to Identify Prognosis of Patients with Solid Tumors
Laura D’Orsi, Biagio Capasso, Giuseppe Lamacchia, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 21, pp. 11588-11588
Open Access | Times Cited: 4
Immunotherapy in Ophthalmic Oncology: Current Trends and Future Directions
Mouayad Masalkhi, Noura Wahoud, Bridget Moran, et al.
Journal of Clinical & Translational Ophthalmology (2025) Vol. 3, Iss. 1, pp. 1-1
Open Access
Page 1 - Next Page

Scroll to top